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Abstract
Background: High dose interferon induction treatment of hepatitis C viral infection blocks viral
production over 95%. Since dose reduction is often performed due to clinical considerations, the
effect of dose reduction on hepatitis C virus kinetics was studied.
Methods: A new model that allowed longitudinal changes in the parameters of viral dynamics was
used in a group of genotype-1 patients (N = 15) with dose reduction from 10 to 3 million units of
interferon daily in combination with ribavirin, in comparison to a control group (N = 9) with no
dose reduction.
Results: Dose reduction gave rise to a complex viral kinetic pattern, which could be only explained
by a decrease in interferon effectiveness in blocking virion production. The benefit of the rapid
initial viral decline following the high induction dose is lost after dose reduction. In addition, in some
patients also the second phase viral decline slope, which is highly predictive of success of treatment,
was impaired by the dose reduction resulting in smaller percentage of viral clearance in the dose
reduction group.
Conclusions: These findings, while explaining the failure of many induction schedules, suggest that
for genotype-1 patients induction therapy should be continued till HCVRNA negativity in serum in
order to increase the sustained response rate for chronic hepatitis C.
Background
The hepatitis C virus (HCV) causes a slowly progressive
liver disease, which may lead to cirrhosis, liver failure and
liver cancer. Currently, about 10,000 patients die in the
US from HCV related disease yearly and this number is ex-
pected to triple in the next 2–3 decades [1] Anti-viral ther-
apy is successful in arresting the progression of the disease
in those patients who reach a sustained clearance of the vi-
rus, currently only 40% of treated patients [2]. Response
to therapy with alpha Interferon injections thrice a week
with or without additional Ribavirin is thought to occur
gradually over time, and research has focused on improv-
ing efficacy by prolonging treatment up to 1 to 2 years [2–
4]. However, reports on viral dynamics analysis show that
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response to interferon is very fast and that a 10 to 1000
fold decrease in viral load can be reached within 24 hours
of treatment. [5–7] The pattern of viral decline seems to
be biphasic, with a rapid viral decline within the first 24–
48 hours followed by a much slower second phase of viral
decline. This biphasic decline is hypothetically caused by
a direct anti-viral effect of interferon in blocking virion
production from infected cells [5].
A strong dependence of the viral decline in the first phase
on the dose of interferon used has been described [5,8].
Nevertheless, it has been shown that it is the second slope
which is the best predictor for response to treatment [5,9].
This slower second phase slope of viral decline has large
variability between patients, and therefore cross sectional
analysis of its dose dependence is hindered. Instead, here
we investigated the longitudinal changes in viral dynamics
in patients going through a dose reduction in order to ass-
es the effect of dose on the second slope. The current mod-
el for HCV dynamics, in which the dynamical parameters
are fixed during treatment, fits the observed biphasic viral
decline in patients treated with fixed Interferon dosages
[5]. However, in this study we adapted the model such
that the dynamical parameters can change over time due
to a change in dose. We now report that early dose reduc-
tion is followed by a rise in viral load, that can only be ex-
plained by a decrease in interferon effectiveness; so the
potential benefit of a rapid viral decline following high
dose induction is often lost.
Methods
A case-control study was performed in an university-based
tertiary referral center. Informed consent was obtained
from all patients, and the human experimentation guide-
lines of the University Hospital Rotterdam were followed
in the conduct of clinical research.
Study population
All 24 HCV genotype-1 patients enrolled in our high-dose
induction studies were evaluated. All patients met the in-
clusion and exclusion criteria previously described [10].
Note that all patients in these studies were considered
"difficult-to-treat", either because they were non-respond-
ers to previous treatment or had cirrhosis and/or high
baseline viral load. Group 1 patients (N = 9) received 10
million units (MU) of Interferon-α -2b (Intron-A, Scher-
ing-Plough) daily for 4 weeks. Group 2 patients (N = 15)
received 10 MU of interferon daily for the first 3 days only,
followed by 3 MU interferon daily from day 3 until day
28. In both groups, ribavirin was given orally in divided
doses of 1,000–1,200 mg daily (according to weight >75
kg). Subsequently, all patients received a maintenance
treatment of minimally 3 MU interferon daily for 52
weeks. The patients' baseline characteristics (Table 1) were
well balanced, except for a trend for larger number of cir-
rhotic patients in group 1.
Detection of Serum HCV RNA
Plasma samples were collected frequently during the first
4 weeks of treatment for HCV RNA detection. Blood sam-
ples were collected in Vacutainer PPT tubes (Becton-Dick-
inson) which were spun directly after collection in order
to avoid RNA breakdown. The spun PPT tubes [11] were
then transported to the virology department where plas-
ma was aliquotted in 5 separate tubes that were stored at
-80°C. Plasma samples were obtained at day 0 (0, 4, 8, 12,
16 hours), day 1 (24, 32 and 40 hours), day 2 (48 and 56
hours), day 3 (72 and 80 hours) day 4, 5, 6 7, 10, 14, 17,
21 and 28 after treatment initiation. Viral load was quan-
tified using the Cobas Amplicor Monitor™ version 2 (Ro-
che Molecular Systems). Since the linearity of quantitative
assays for high numbers of viral copies has been question-
able [12] we routinely diluted samples and re-tested, if the
early quantification of that sample was higher than 106
copies/ml.
Mathematical Modeling
Viral kinetics were analyzed using a modification of a pre-
viously described mathematical model for viral dynamics
[5], for which the analytical solution is,
V(t) = V0 {A exp[-λ 1(t  - t0)] + (1 - A) exp[-λ 2(t - t0)]} for
(t > t0)   (Eq.  1)
Where
λ 1,2 = 1/2 {(c + δ ) ± [(c - δ )2 + 4(1 - ε )(1 - H) cδ ]1/
2}
(Eq. 2)
A = (ε c - λ 2)/(λ 1 - λ 2)   (Eq. 3)
This formula contains several dynamical parameters (c, δ ,
H and ε ) which may vary per patient according to the best
fit of the actual data, but are constant over time. c de-
Table 1: Patient baseline characteristics.
Patient characteristics Group 1 (1) Group 2 (1)
Number of patients 9 15
Median age 44 47
Male/Female 7 / 2 11 / 4
Race (Caucasian / Asian) 7 / 2 15 / 0
Pre-treatment RNA HCV 5.5. ×  106 7.5 ×  106
Genotype 1 All All
Median ALT at baseline 89 122
Cirrhosis/No-cirrhosis 4 / 5 1 / 14
Previous NR / other * 6 / 3 11 / 4
*) Non-sustained responder to previous therapy or previously 
untreated patients with cirrhosis and genotype 1.BMC Gastroenterology 2001, 1:14 http://www.biomedcentral.com/1471-230X/1/14
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scribes the clearance rate of free virus, with the corre-
sponding virus half-life of ln(2)/c. δ  describes the loss rate
of productively infected cells, with the corresponding cel-
lular half-life of ln(2)/δ . The effect of interferon can be
modeled here either by a block of de-novo cell infection
with effectiveness H (0 ≤  H ≤  1), or block of virion produc-
tion with effectiveness ε  (0 ≤  ε  ≤  1). The logarithmic drop
in viral decline during the first phase (24–48 hours) of
treatment can be approximated by log(1-ε ). The 2nd phase
slope can be approximated by ε  times δ  when H << 1, or
by δ  alone when H ≅  1.
To investigate the effect of reducing treatment dose, all the
above dynamical parameters were allowed to change over
time in the solution, e.g. for interferon effectiveness in
blocking virion production, ε , we use the function ε  (t) :
for t ≤  t1 : ε (t) = ε 1   (Eq.  4)
for t > t1 : ε  (t) = (ε 1 - ε 2) exp(-k(t - t1)) + ε 2
where t1 is the time of dose change and k is a exponential
rate representing how rapid does the change in interferon
dose effect the change in the parameter. Thus, the block-
ing effectiveness starts at ε 1 (for t ≤  t1), and changes with
an exponential transition to ε 2 (after (t-t1) >>1/k). The
same functional form was used to investigate changes in
H (from H1 to H2), δ  (from δ 1 to δ 2), and c (from c1 to c2).
It is important to note that we do not explicitly model in
Eq. 1 the dynamics of viral replication after the dose re-
duction, but rather replace the fixed parameters by time
dependent parameters in the original analytical solution
obtained with fixed parameters. Nevertheless, we have
tested this approximation by simulating a modification of
the original differential equation model [5] where chang-
es in the dynamical parameters were allowed to change at
the time of dose reduction. We found no significant differ-
ence between the simulation of the full modified differen-
tial equation model and the modified analytical solution.
Since we only have 2–3 viral measurements immediately
after dose reduction, we can not estimate the appropriate
replication parameters and thus chose to use the simple
approximation given in Eq 1.
To estimate HCV viral kinetic parameters for each patient,
the logarithm of V(t) in Eq. 1 (using ε  (t) from Eq. 4) was
fit to the logarithm of the viral load data by a non-linear
least squares method using the Madonna software (R.I.
Macey and G.F. Oster, Berkeley, CA, USA). Two patients in
group 2 were missing viral load data during the first week
of treatment and one patient had a null response (less
than 3 fold change in viral load during treatment) and
therefore their viral kinetics could not be fitted.
Statistical analysis
The Fisher-exact test (2 ×  2 tables) and the Chi-square test
(N ×  N tables) were used to determine the statistical sig-
nificance of the distribution of categorical variables be-
tween groups. The non-parametric independent (or
related) Mann-Whitney rank sum test was used to deter-
mine the statistical significance of differences in continu-
ous variables between the two groups (or of changes in
the parameters within the same patients). Correlation
among parameters, or between parameters and baseline
values, was evaluated using the Spearman non-parametric
test. Significance was established at P < 0.05.
Results
The biphasic decline previously reported [5–7,13] de-
scribes the viral kinetics during the first month for all pa-
tients in group 1 (Fig 1, Fig 2a), for whom interferon dose
was kept constant. In contrast, we observed a complex dy-
namic pattern for 11 out of 12 evaluable patients in group
2 (Fig 1, Fig 2b,c,d). In these patients, a rapid decline oc-
curred during the first day, followed by a slower decline
on the second and third days, at which point a rapid in-
crease in viral load (mean 0.8 [range 0–1.3] log copies/
ml) is observed within 24–48 hours after the reduction in
interferon dose. Thereafter, viral load again declined with
a mean exponential slope comparable to the second
phase slope in group 1.
We have tried to fit the viral kinetics of the patients in
group 2 with several models, in each one of them allow-
ing to change one parameter (ε , H, c or δ ) at the time of
dose reduction. The only model that was able to qualita-
tively reproduce the observed kinetics was the one which
allowed a longitudinal change in the interferon effective-
ness in blocking virion production (ε ) as function of the
interferon dose (Eq. 4). By only allowing to change the in-
terferon effectiveness in blocking de-novo infection (H),
death rate of infected cells (δ ) or the clearance rate of free
virions (c), it was not possible to fit the observed data.
When assuming the major effect of interferon is to block
virion production in a dose dependent way (1 > ε 1 > ε 2 >
0), it was possible to fit the data both with H = 0 or H = 1.
Thus it was not possible to determine if interferon also
blocks de-novo infection, in addition to blocking virion
production, or not. Varying H between 0 and 1 only gives
rise to minimal changes in the estimate of ε  and c, while
somewhat affecting the estimate of δ  when ε  is smaller
than 0.98 (minimal estimate of δ  obtained for H = 1, and
maximal estimate for H = 0). Moreover, when allowing ε
to change at the time of dose reduction, it was not possi-
ble to rule out that the other parameters also change at the
same time.
For simplicity, and since our data only implies minute ef-
fects due to changes in the other parameters, we have as-BMC Gastroenterology 2001, 1:14 http://www.biomedcentral.com/1471-230X/1/14
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sumed a change occurs only in ε  when estimating the
dynamical parameters. In addition, we needed to estimate
the transition rate k (Eq. 4) from ε 1 to ε 2. It was not pos-
sible to get a unique estimate of k for each patient individ-
ually, with only 2–3 measurements during the rebound.
Since using k = 1 up to 20 did not significantly affect the
estimate of the other parameters, we have assumed k = 2
for all patients such that the effect of ε 1 vanishes within
24–48 hours after the dose reduction in accordance to the
observed data.
The estimates obtained by non-linear fitting of each pa-
tient's viral kinetics individually are given in Table 2. As
expected the baseline viral load, the half-life of free virions
and the initial effectiveness in blocking virion production,
all related to the first phase decline, were similar between
the 2 groups. Mean half-life of free virions for all patients
was 3.0 hours ± standard deviation of 1.6 hours, similar to
that derived in previous studies for interferon-α  mono-
therapy (2.7 hours) [5]. The mean effectiveness in block-
ing virion production for all patients was 95.6% ± 6.5%
for the 10 MU interferon dose. For group 1 the non-linear
fit (with Eq. 4) did not give rise to a significant change in
ε  over time, in accordance to the constant daily interferon
dose used in these patients (insert Fig 2a). For group 2,
however, a significant (p < 0.005) decrease in effectiveness
of blocking production was observed (inserts Fig 2b,c,d,
Figure 1
Group 1 (N = 9) received a continues dose of 10 MU INTERFERON daily for 28 days. Group 2 (dose reduction group, N = 15)
reduced from 10 MU INTERFERON daily to 3 MU INTERFERON daily after 3 days of treatment. After the viral load data was
log-transformed, the geometric means were calculated for the 2 groups for each time-point of viral load measurement. The
created mean viral for group 1 clearly shows a biphasic decline in viral load as previously described for chronic HCV. Viral
decline in the patients with a INTERFERON dose reduction (line Group 2) is more complex: a rebound in viral load is
observed coinciding with the time of INTERFERON dose reduction.
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Fig 3a) from an average of ε 1 = 94% ± 8% to ε 2 = 69% ±
27%. The effectiveness of interferon with 10 MU (ε 1) and
with 3 MU (ε 2) were pair wise correlated (R = 0.8, P <
0.001).
Cross-sectionally there was no difference observed be-
tween the 2 groups in the death rate of infected cells (Ta-
ble 2) or in the second phase slope (Fig 3b). However,
longitudinal analysis of group 2 patients revealed a signif-
icant decrease from the predicted second phase slope,
which would have occurred without a dose reduction, to
the actual slope after dose reduction in 4 out of 12 pa-
tients (Fig 4a). These are the patients with the largest de-
crease (range 20% to 68%) from ε 1 to ε 2, since the second
slope is a linear function of the interferon effectiveness in
blocking production (ε ).
The clinical consequences of the viral dynamics data relate
to the predicted time of HCV RNA negativity, which is
strongly dependent on the second phase slope. The pre-
dicted time to HCV-negativity with the biphasic model
(median 3.5 weeks) was confirmed by the observed indi-
vidual data of group 1 patients (median 4 weeks), and the
dose-reduction model (with the reduced 3 MU dose) pre-
Figure 2
In figure 2a the actual viral load measurements (red dots) and the fitted viral decline curve using Eq. 1 (black line) is presented
of one of the patients (No 1-I) who receive 10 MU INTERFERON daily for 28 days. The actual decline in viral load in this
patient is best described by the original bi-phasic model. In figure 2b,c,d the actual viral load (red dots) and the fitted viral
decline using the modified model allowing for a change in INTERFERON efficacy as described in Eq.5 is presented (black line).
The actual viral decline could only be correctly fitted by using our modified model. The red lines represent the calculated bi-
phasic decline curve for a continues 10 MU INTERFERON regimen in the patients of group 2 by fitting only the observed viral
load during the treatment period of 10 MU daily in the original model. The green line represents the calculated viral decline
curve as if a continues treatment of 3 MU INTERFERON daily was given from the start of treatment (only the viral load during
3 MU INTERFERON are fitted). Note that the difference in the slope between the calculated decline curves for 10 MU versus
3 MU (red versus green lines) is dependent on the change in interferon efficacy after dose reduction (inserts). Patients 2-H was
calculated to become HCV RNA negative within 14 days if 10 MU INTERFERON was continued (red line figure 2-d), but after
dose reduction the actual viral decline curved shifted dramatically due to a strong decline in INTERFERON efficacy (green line).
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Figure 3
Figure 3a. Interferon efficacy in blocking production (%) is displayed for group 1 and group 2 (logarithmic scale). For the
patients that received a dose reduction after 3 days of treatment (group 2), both the efficacy for the initial, 10 MU INTER-
FERON daily period, is displayed as well as the reduced efficacy after the dose reduction to 3 MU daily. Note that the initial
interferon efficacy between group 1 and 2 does not differ. After the dose reduction the interferon efficacy is reduced in 11/12
patients in group 2 (connected black dots). Figure 3b. The slopes of the second phase decline (days-1) is represented per
patient (black squares) for both groups. No differences between both groups could be observed in this study.
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dicted the time to HCV-negativity in group 2 patients (me-
dians 12 and 14.5 weeks, Table 3). Reducing the
interferon dose to 3 MU daily decreased the predicted
number of patients that would become HCV-negative
within 12 weeks from 12/15 with the 10 MU dose to only
7/15 with the reduced 3 MU dose, as indeed confirmed by
the actual individual data (8/15).
Discussion
Our results indicate that the effect of interferon dose re-
duction on viral dynamics can be completely attributed to
decrease in the effectiveness of interferon in blocking vir-
ion production (ε ). Changes in other parameters, such as
blocking de-novo infection (H) loss rate of infected cells
(δ ) and clearance rate of free virions (c), without a change
in blocking production, can not reproduce the observed
kinetics. The longitudinal dose dependence of the inter-
feron anti-viral effectiveness observed here corroborates
the dose dependence of interferon effectiveness previous-
ly described only cross-sectionally [5]. The strength of the
current results is that the dose dependence of the effective-
ness cannot be attributed to baseline differences between
the patients. Since longitudinal changes in the other pa-
rameters of this model (such as H, δ  and c) do not give rise
Table 2: Results of non-linear fitting of viral dynamics
Patient (1) Initial viral load (log copies/ml) % blocking production Half-life(2) of 
free virions 
(hours)
Half-life of infected 
cells (days)
During 10 MU qd After reduction to 3 MU qd minimal and maximal 
estimates (3)
1-A 6.9 98.4 2.3 8.7–8.8
1-B 6.9 99.9 2.5 3.0–3.0
1-C 6.7 99.5 2.2 1.7–1.7
1-D 6.1 86.9 1.9 7.8–9.0
1-E 5.8 99.5 5.3 4.4–4.5
1-F 6.4 98.5 6.4 3.2–3.2
1-G 7.0 95.1 1.8 6.1–6.4
1-H 7.1 99.8 1.7 1.1–1.1
1-I 7.4 98.9 3.3 4.9–4.9
Group 1(4) mean (std) 6.7 (0.5) 97.4 % (0.04) 3.0 hours (1.7) 4.5–4.7 days (2.6–2.8)
2-A 7.3 93.0 62.5 1.8 4.8–7.7
2-C 6.8 98.1 78.5 3.3 0.9–1.2
2-E 6.7 93.8 86.0 3.3 7.1–8.2
2-F 6.5 99.6 95.2 1.9 1.0–1.0
2-G 7.2 97.8 85.0 3.3 4.0–4.7
2-H 7.3 95.5 27.8 3.9 1.2–4.7
2-I 6.1 98.1 88.0 1.1 11.8–13.5
2-J 7.1 99.9 98.0 1.6 3.4–3.4
2-K 7.1 71.4 25.2 2.1 2.6–2.7
2-L 6.3 99.6 99.6 6.9 2.2–2.3
2-M 7.4 93.0 81.1 2.1 12.0–14.8
2-N 6.8 92.4 33.2 3.6 2.5–7.7
Group 2(4) mean (std) 6.9 (0.4) 94.3% (0.08) 69.1% (**) (26.6) 2.9 hours (1.6) 4.4–6.7 days (3.9–4.6)
1) Fitting was not done for: patients 2-B (non-detectable at day 2 on), 2-D (Null-response), 2-O (missing data and rebound). 2) For group 1 half-life 
of free virions is only a maximal estimate because only samples from 0, 8 and 24 hours were available. 3) Minimal and maximal estimates of the half-
life of infected cells was estimated assuming H = 1 and H = 0 respectively in Eq 2. 4) No statistically significant differences in any parameter between 
the two groups. **) Statistically significant (p < 0.002) difference in percentage blocking production before and after dose reduction in group 2.BMC Gastroenterology 2001, 1:14 http://www.biomedcentral.com/1471-230X/1/14
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to significant differences in the kinetics, we can not rule
out combined effects of changes in the other parameters
concomitantly with the change in effectiveness of block-
ing production (ε ).
In turn, the dose dependency of the interferon effective-
ness determines the result of both the 1st phase and the
2nd phase kinetics. The effectiveness in blocking virion
production with 10 MU before dose reduction (mean
95.6% and a mean viral decline of 1.8 log cp/ml) was sim-
ilar to that of a previous study with 10 MU interferon
(96%) [5]. However, we show that the benefit of the ini-
tial viral decline due to 3 days of high induction dose was
lost after the dose reduction in almost all patients (Fig 1,
3). The effectiveness in blocking virion production with 3
MU after the dose reduction (mean 69.1% and a mean vi-
ral decline of 0.7 log cp/ml) was similar to that estimated
in a previous study with 3 MU interferon initially (70%)
[8]. As a consequence, the viral kinetics after the dose re-
duction in group 2 patients is similar to the kinetics that
would have been obtained if the patients had started with
the reduced dose to begin with (green line Fig 2).
In contrast to the 1st phase viral decline, which exponen-
tially depends on the interferon effectiveness, the 2nd
phase slope is a linear function of the effectiveness in
blocking virion production. This slope is the most predic-
tive parameter for treatment outcome, with a threshold of
0.13 days-1 below which no sustained response was ob-
served [5] While the increase observed in viral load imme-
Figure 4
The effect of the change in interferon efficacy after the dose reduction (x-axis) for the patients in group 2 is related to the
change in slope of the second phase viral decline (open circles: second phase slope before dose reduction; horizontal lines: sec-
ond phase slope after dose reduction). In 4 patients the slope of the second phase reduces drastically, note that 3/4 of these
patients have the largest reduction in interferon efficacy. The dashed line reflects the threshold of 0.13 days-1 below which no
sustained response was observed.
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diately after dose reduction can delay the time to
negativity by several weeks at the most (patients 2-J and 2-
C Fig 2), the decrease in the second phase slope can radi-
cally reduce the chance for HCV-RNA negativity (patient
2-H Fig 2). Therefore the decrease in the second slope
could be crucial for their success of treatment. Indeed, the
number of patients predicted to become HCV-negative
within 12 weeks with the high induction dose was drasti-
cally reduced due to the dose reduction (compare the 10
MU column versus 3 MU column in Table 3).
Interestingly, the results obtained here are for interferon
and ribavirin combination treatment, while the results
from previous studies [5,8] are for interferon monothera-
py. On the other hand, in this study most patients are
non-responders or cirrhotic rather than normal naïve pa-
tients as in the previous studies [5,8]. Thus, we can not
conclude if ribavirin has an additive effect on initial viral
decline or not.
Is induction treatment beneficial at all considering that
following dose reduction the virus rebounds back to the
level it would reach anyway with the reduced dose? Previ-
ous studies with a longer period of induction treatment
(14 days) do not show a consistent viral rebound as ob-
served here [14]. Moreover, studies of prolonged induc-
tion treatment (> 28 days) do not show any re-emergence
of virus production [15]. Therefore, it could be suggested
that an induction period of 3 days is too short, but longer
induction periods, which continue until HCVRNA nega-
Table 3: Predicted and observed time to HCV RNA negativity
Patient Predicted time (weeks) to HCV RNA negativity(1) 
with 10 MU/daily
Predicted time (weeks) to HCV RNA 
negativity(1) with 3 MU/daily
First observedHCV RNA neg-
ativity(1) (weeks)
1-A 11 12 (2)
1-B 2 2
1-C 1.5 2
1-D 12 4–8
1-E 2.5 2
1-F 3.5 4
1-G 10.5 4–8
1-H 1 1
1-I 9 Positive at 24 weeks (3)(4)
Group 1: HCV neg 
before 12 weeks
9 / 9 patients 8 / 9 patients
2-A 9 16 Positive at 24 weeks (3)
2-B 1 1 1
2-C 1 2 1.5
2-D Never Never Positive at 24 weeks (3)
2-E 11 13 4–8
2-F 1 1.5 1.5
2-G 5.5 7 4–8
2-H 3 10 12–16
2-I 11 18 Positive at 24 weeks (3)
2-J 3 5 4
2-K 7.5 24 Positive at 24 weeks (3)
2-L 1.5 1.5 1.5
2-M 23 30 8–12
2-N 4 16 Positive at 24 weeks (3)
2-O Never Never Positive at 24 weeks (3)
Group 2: HCV neg 
before 12 weeks
12 / 15 patients 7 / 15 patients 8 / 15 patients
Detection level for HCV RNA negativity is at < 500 copies/ml. 2) Patient 1-D had a viral breakthrough after 12 weeks and was HCV RNA positive 
at 24 weeks of treatment. 3) Patients with positive HCV RNA at 24 weeks stopped treatment according to protocol. 4) Patient 1-I was non-compli-
ant from 8 weeks on according to self-reportBMC Gastroenterology 2001, 1:14 http://www.biomedcentral.com/1471-230X/1/14
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tivity in serum, might give rise to continuous suppression
of viral replication. In all likelihood this concept may
partly explain the increased efficacy of pegylated interfer-
on [16,17] since the rather constant interferon levels with
this type of interferon result in a constant block of virus
production.
Conclusions
Dose reduction to 3 MU daily after 3 days of 10 MU of in-
terferon daily in HCV genotype-1 patients negated the ex-
tra virus suppressive effectiveness of the induction dose.
These observations, while explaining the failure of many
induction schedules suggests that induction therapy
should be continued till HCV RNA negativity in serum in
order to increase the sustained response rate in chronic
hepatitis C.
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